Please login to the form below

Not currently logged in
Email:
Password:

Valeant appoints company group chairman

Ari Kellen joins from McKinsey & Company

Fast-growing Canadian pharma company Valeant Pharmaceuticals has appointed Dr Ari Kellen as executive VP and company group chairman.

Dr Kellen joins from McKinsey & Company where he was a senior partner at the consultancy firm's mid-Atlantic office.

He spent 22 years at McKinsey leading a number of a studies for healthcare companies, including corporate strategies for boards and top management teams, business unit strategies for medical device, pharma and biotech, and health care services clients, and regional and country growth strategies.

J Michael Pearson, chairman and CEO of Valeant, said: "Ari's broad experience in developing comprehensive growth strategies for healthcare companies will be invaluable to us as we continue to expand our successful growth trends.

“After having worked with Ari for many years, I know that not only will he fit in well with the rest of the team, but he will be a strong advocate for the long-term shareholder focused culture at Valeant."

28th November 2013

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Top Pharma News

TopPharmaNews.com is a global pharma magazine dedicated to delivering fresh news to society. The team at the TopPharmaNews.com cater non-biased,...

Latest intelligence

The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch
...

Infographics